Armis Identifies the Riskiest Assets Introducing Threats to Global Businesses
5.9.2023 16:00:00 EEST | Business Wire | Press release
Armis, the leading asset visibility and security company, today released new research identifying the riskiest connected assets posing threats to global businesses. Findings highlight risk being introduced to organizations through a variety of connected assets across device classes, emphasizing a need for a comprehensive security strategy to protect an organization’s entire attack surface in real-time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905844605/en/
Source: Data from the Armis Asset Intelligence Engine collected between August 2022 and July 2023.
“Continuing to educate global businesses about the evolving and increased risk being introduced to their attack surface through managed and unmanaged assets is a key mission of ours,” said Nadir Izrael, CTO and Co-Founder of Armis. “This intelligence is crucial to helping organizations defend against malicious cyberattacks. Without it, business, security and IT leaders are in the dark, vulnerable to blind spots that bad actors will seek to exploit.”
Armis’ research, analyzed from the Armis Asset Intelligence Engine, focuses on connected assets with the most attack attempts, weaponized Common Vulnerabilities and Exposures (CVEs) and high-risk ratings to determine the riskiest assets.
Assets With The Highest Number of Attack Attempts
Armis found the top 10 asset types with the highest number of attack attempts were distributed across asset types: IT, OT, IoT, IoMT, Internet of Personal Things (IoPT) and Building Management Systems (BMS). This demonstrates that attackers care more about their potential access to assets rather than the type, reinforcing the need for security teams to account for all physical and virtual assets as part of their security strategy.
Top 10 device types with the highest number of attack attempts:
- Engineering workstations (OT)
- Imaging workstations (IoMT)
- Media players (IoT)
- Personal computers (IT)
- Virtual machines (IT)
- Uninterruptible power supply (UPS) devices (BMS)
- Servers (IT)
- Media writers (IoMT)
- Tablets (IoPT)
- Mobile phones (IoPT)
“Malicious actors are intentionally targeting these assets because they are externally accessible, have an expansive and intricate attack surface and known weaponized CVEs,” said Tom Gol, CTO of Research at Armis. “The potential impact of breaching these assets on businesses and their customers is also a critical factor when it comes to why these have the highest number of attack attempts. Engineering workstations can be connected to all controllers in a factory, imaging workstations will collect private patient data from hospitals and UPSs can serve as an access point to critical infrastructure entities, making all of these attractive targets for malicious actors with varying agendas, like deploying ransomware or causing destruction to society in the case of nation-state attacks. IT leaders need to prioritize asset intelligence cybersecurity and apply patches to mitigate this risk.”
Assets With Unpatched, Weaponized CVEs Vulnerable to Exploitation
Researchers identified a significant number of network-connected assets susceptible to unpatched, weaponized CVEs published before 1/1/2022. Zooming in on the highest percentage of devices of each type that had these CVEs between August 2022 and July 2023, Armis identified the list reflected in Figure A. Unpatched, these assets introduce significant risk to businesses.
Assets with a High-Risk Rating
Armis also examined asset types with the most common high-risk factors:
- Many physical devices on the list that take a long time to replace, such as servers and Programmable Logic Controllers (PLCs), run end-of-life (EOL) or end-of-support (EOS) operating systems. EOL assets are nearing the end of functional life but are still in use, while EOS assets are no longer actively supported or patched for vulnerabilities and security issues by the manufacturer.
- Some assets, including personal computers, demonstrated SMBv1 usage. SMBv1 is a legacy, unencrypted and complicated protocol with vulnerabilities that have been targeted in the infamous Wannacry and NotPetya attacks. Security experts have advised organizations to stop using it completely. Armis found that 74% of organizations today still have at least one asset in their network vulnerable to EternalBlue – an SMBv1 vulnerability.
- Many assets identified in the list exhibited high vulnerability scores, have had threats detected, have been flagged for unencrypted traffic or still have the CDPwn vulnerabilities impacting network infrastructure and VoIPs.
- Half (50%) of pneumatic tube systems were found to have an unsafe software update mechanism.
Additional research from Armis is available on the riskiest OT and ICS devices across critical infrastructure industries as well as the riskiest medical and IoT devices in clinical environments.
Learn more about Armis at www.armis.com.
About Armis
Armis, the leading asset visibility and security company, provides the industry’s first unified asset intelligence platform designed to address the new extended attack surface that connected assets create. Fortune 100 companies trust our real-time and continuous protection to see with full context all managed, unmanaged assets across IT, cloud, IoT devices, medical devices (IoMT), operational technology (OT), industrial control systems (ICS), and 5G. Armis provides passive cyber asset management, risk management, and automated enforcement. Armis is a privately held company and headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905844605/en/
Contact information
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
